At the present time, ALK inhibitors have not yet been approved for use in other ALK-driven cancers than NSCLC; however, some studies have reported remarkable responses, and less frequent relapses, to ALK inhibitors in patients with ALK-positive ALCL and IMT. Here, ALK is linked to non-small cell lung carcinoma.